Quick answer
In localised prostate cancer, the European guideline considers a life expectancy of more than 10 years mandatory for surgery or radiotherapy to bring any benefit.4 One way to estimate that time is the Charlson index, which adds points for age and for other conditions. From the index, an equation from the original 1987 study estimates the chance of being alive in 10 years.1 It is a group average, based on patients from the 1980s, and it does not say how long any one person will live. Bring the result to your consultation.
Calculate your Charlson index
You need your age and the list of conditions you have or have had. If you are not sure how severe one of them is, ask the doctor who follows that condition.
Your answers stay in your browser. Nothing is sent, stored or saved in cookies, and everything is cleared when you close the page.
Result
Enter your age, tick your conditions and tap Calculate.
The result is copied into the form below. You can change the text before sending it.
The calculator adds the points for age and conditions and shows the estimated chance of being alive in 10 years. Liver disease, diabetes and another cancer count only once, at their most severe level. Other tools are on the urology calculators page.
Why life expectancy matters
Treatment with curative intent, surgery or radiotherapy, takes time to show its benefit. That is why the European guideline considers a life expectancy of more than 10 years mandatory for local treatment of localised cancer to bring any benefit.4
Other conditions matter more than age. The guideline points out that, 10 years after watchful waiting, most men with a high comorbidity score had died from other causes, whatever their age or the aggressiveness of the tumour.4 It names the Charlson index and the CIRS-G scale as ways of measuring these conditions. It also recommends, as a strong recommendation, using each man's life expectancy, health status and comorbidity in decisions, and screening health status with tools such as the G8, the mini-COG and the Clinical Frailty Scale.4
The page up to what age can the prostate be operated on shows what the studies say about surgery after 70 and after 75. In low-risk cancer, life expectancy also changes the type of follow-up.
The points in the index
These are the weights of the Charlson index, from the original 1987 table:1,3
| Points | Conditions |
|---|---|
| 1 | Heart attack, heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic lung disease, connective tissue disease, ulcer disease, mild liver disease, diabetes |
| 2 | Hemiplegia, moderate or severe kidney disease, diabetes with organ damage, any tumour, leukaemia, lymphoma |
| 3 | Moderate or severe liver disease |
| 6 | Metastatic solid tumour |
Age adds 1 point for each decade over 40: 0 points under 50, 1 from 50 to 59, 2 from 60 to 69, 3 from 70 to 79 and 4 from 80 onwards.3 In the 1994 study, each comorbidity point and each decade of age raised the risk of death by about the same amount, around 1.4 times.2
The prostate cancer being assessed does not go into the calculation, because the idea is to measure the weight of the other conditions. A previous cancer of another organ does.
How the 10-year chance is calculated
The chance of being alive in 10 years comes from the equation 0.983 to the power of e^(0.9 × age-adjusted index). The number 0.983 is the chance that a theoretical low-risk group is alive in 10 years, and 0.9 measures how much each point raises the risk. The equation comes from the validation phase of Charlson's original study and is the one used by medical calculators.1,3
| Age-adjusted index | Estimated chance of being alive in 10 years |
|---|---|
| 0 | 98% |
| 1 | 96% |
| 2 | 90% |
| 3 | 77% |
| 4 | 53% |
| 5 | 21% |
| 6 | 2% |
| 7 or more | less than 1% |
An example: a 72-year-old man gets 3 points for age. If he has had a heart attack and has diabetes without organ damage, he adds 2 more. The index is 5, and the estimated chance of being alive in 10 years is 21%.
What the calculation does not show
The index was created in 559 patients, and the authors themselves wrote that the number of patients with each condition was small and that the method needed refining in larger groups.1 The equation was built from patients in the 1980s and does not take into account how the treatment of these conditions has changed since then. Nor does it measure severity within each condition: a small, old heart attack counts the same as a large, recent one.
The European guideline says survival must be assessed individually and points to other useful information, such as population life tables and walking speed, which on its own already helps predict life expectancy.4 That is why the calculator gives a group estimate and does not tell you which treatment to have.
My approach
At the consultation, I take into account your age, your health, your other conditions and what you want to preserve, as well as the cancer itself. I continue PSA testing while a man is healthy and has a life expectancy of more than 10 years. In low-risk cancer, I assess each case individually.
Before major surgery, such as robotic radical prostatectomy, I always ask for a cardiology assessment. For men with poorly controlled diabetes, I also ask for an endocrinology assessment before surgery. If you already have a diagnosis and would like another opinion, a second opinion can be done entirely online, in English, with your tests sent in advance.
Send your case
If you have received a diagnosis and would like my opinion on your case before a consultation, fill in the form below. Please also list your other conditions and the medicines you take. The form goes to my office, and you will get a reply within 24 hours by email or WhatsApp. It does not replace a consultation: it helps plan the next step.
Frequently asked questions
Why does life expectancy matter in prostate cancer treatment?+
Because the benefit of local treatment takes time to appear. The European guideline considers a life expectancy of more than 10 years mandatory for local treatment of localised cancer to bring any benefit. It also says that other conditions are a strong predictor of death from other causes and matter more than age.4
What is the Charlson index?+
It is a score of comorbid conditions, in which each condition has a weight according to its risk of death. It was created in 1987 in a group of 559 patients and tested in another group of 685 patients followed for 10 years.1 In 1994, the authors showed that an extra decade of age weighed about the same as 1 comorbidity point and tested an index that adds the two together.2
How does the calculator estimate the chance of being alive in 10 years?+
With the equation 0.983 to the power of e^(0.9 × age-adjusted index). It comes from Charlson's original 1987 study and is the equation used by medical calculators.1,3 With 0 points, the estimate is 98%; with 3 points, 77%; with 5 points, 21%.
Does the result tell me how long I will live?+
No. It is a group average, calculated from patients in the 1980s. The European guideline says survival must be assessed individually and recommends using each man's life expectancy, health status and comorbidity in decisions, as a strong recommendation.4 The calculator's number is a starting point for the conversation at your consultation.
Up to what age is PSA testing worthwhile?+
The European guideline recommends offering an individualised strategy for early detection to well-informed men with a life expectancy of at least 15 years, as a weak recommendation.5 In my practice, I continue PSA testing while a man is healthy and has a life expectancy of more than 10 years.
Does the calculator apply if I have a condition that is not on the list?+
No. It only adds up the conditions in the Charlson index. Anyone with another serious condition not on the list needs an individual assessment, and in that case the calculator may overestimate the chance of being alive in 10 years. The authors themselves wrote that the number of patients with each condition in the original study was small.1
Who assesses life expectancy before prostate cancer treatment in São Paulo?+
I see men with prostate cancer in São Paulo and take age, general health and other conditions into account when choosing treatment. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275, and a reference in prostate cancer. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. PubMed
- Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251. PubMed
- Do SY, Bush DA, Slater JD. Comorbidity-adjusted survival in early stage lung cancer patients treated with hypofractionated proton therapy. J Oncol. 2010;2010:251208. PubMed
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment (estimating life expectancy and health status, section 6.1). European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: diagnostic evaluation (early detection). European Association of Urology; 2026. EAU
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
